This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Henan Zhiwei Biomedicine Co., Ltd., Henan Zhiwei Biomedicine Co., Ltd.. Active years: 2025-2026.
Company Filing History:
1 out of 1 
1 out of 1 Years Active: 2025-2026
Title: Yang Li: Innovator in Bruton's Tyrosine Kinase Inhibitors
Introduction
Yang Li is a notable inventor based in Xinxiang, China. He has made significant contributions to the field of biomedicine, particularly in the development of compounds that target Bruton's Tyrosine Kinase (BTK). With a total of 2 patents, his work is pivotal in addressing various diseases.
Latest Patents
Yang Li's latest patents include innovative compounds aimed at treating autoimmune diseases, inflammatory diseases, cancer, and potentially allergies. The first patent, titled "Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors," discloses a series of substituted imidazolecarboxamide compounds that serve as BTK inhibitors. The second patent, "Substituted 1-amino-1H-imidazole-5-carboxamide as Bruton's tyrosine kinase inhibitors," presents a compound or its pharmaceutically acceptable variants that also function as BTK inhibitors.
Career Highlights
Throughout his career, Yang Li has worked with Henan Zhiwei Biomedicine Co., Ltd., where he has contributed to the advancement of biomedicine through his innovative research and development efforts. His work has been instrumental in creating therapeutic options for challenging medical conditions.
Collaborations
Yang Li has collaborated with notable colleagues such as Chunhua Ma and Yuqin Jiang, enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Yang Li's contributions to the field of biomedicine, particularly through his patents on Bruton's Tyrosine Kinase inhibitors, highlight his role as an influential inventor. His work continues to pave the way for new treatments in the medical field.